Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX) and Incyte Corp (INCY)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pacira Pharmaceuticals (NASDAQ:PCRX) and Incyte Corp (NASDAQ:INCY).

Pacira Pharmaceuticals (PCRX)

In a report released today, Dewey Steadman from Canaccord Genuity maintained a Hold rating on Pacira Pharmaceuticals, with a price target of $45. The company’s shares opened today at $43.35.

According to TipRanks.com, Steadman is a 4-star analyst with an average return of 7.5% and a 41.1% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Perrigo Company plc, and Endo International.

Currently, the analyst consensus on Pacira Pharmaceuticals is a Moderate Buy with an average price target of $51.33.

See today’s analyst top recommended stocks >>

Incyte Corp (INCY)

Cowen & Co. analyst Marc Frahm maintained a Buy rating on Incyte Corp today. The company’s shares opened today at $73.44.

According to TipRanks.com, Frahm is a 3-star analyst with an average return of 9.6% and a 100.0% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Adaptimmune Therapeutics, and Blueprint Medicines.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Incyte Corp with a $83.20 average price target, a 13.3% upside from current levels. In a report issued on August 30, Argus Research also maintained a Buy rating on the stock with a $83 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts